Nail changes due to docetaxel - A neglected side effect and nuisance for the patient

Supportive Care in Cancer

Volumn 15, Issue 10, 2007, Pages 1191-1197

  Winther, Dorte ^a,e   Saunte, Ditte Marie ^b   Knap, Marianne ^c   Haahr, Vera ^d   Jensen, Anders Bonde ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b STATENS SERUM INSTITUT   (Denmark)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

^d VIBORG HOSPITAL   (Denmark)

^e NONE   (Denmark)

Author keywords

Cancer mammae; Docetaxel; Functional impairment; Nail changes

Indexed keywords

DOCETAXEL;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER PATIENT; CLINICAL FEATURE; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAIL BED; NAIL DISEASE; NEUROPATHY; PATIENT INFORMATION; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SIDE EFFECT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DENMARK; FEMALE; HUMANS; MALE; MIDDLE AGED; NAILS, MALFORMED; TAXOIDS;

EID: 34648833218     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-007-0232-0     Document Type: Article

References (19)

1. National Board of Health (2004) Cancer incidence in Denmark, 2000. National Board of Health, Denmark
2. Correia O, Azevedo C, Pinto Ferreira E, Braga Cruz F, Polonia J (1999) Nail changes secondary to docetaxel (taxotere). Dermatology 198(3):288-290
3. Doval DC, Pavithran K (2002) Nail changes due to docetaxel. Br J Dermatol 146(4):709-710
4. Drake LA, Scher RK, Smith EB, Faich GA, Smith SL, Hong JJ, Stiller MJ (1999) Effect of onychomycosis on quality of life. J Am Acad Dermatol 38(5):702-704
5. Howard A, Nicolopoulos J (2002) Docetaxel-induced nail dystrophy. Australas J Dermatol 43(4):293-296
6. Hussain S, Anderson DN, Salvatti ME, Adamson B, McManus M, Braverman AS (2000) Onycholysis as a complication of systemic chemotherapy. Cancer 88(10):2367-2371
7. Markman M (2003) Managing taxane toxicities. Support Care Cancer 11:144-147
8. Minisini AM, Tosti A, Sobrero AF, Mansutti M, Piraccini BM, Sacco C, Puglisi F (2003) Taxane-induced nail changes: incidence, clinical presentation and outcome. Ann Oncol 14:333-337
9. Nilsson J, Svejgaard EL (2004) Onychomycosis in Denmark: prevalence of fungal nail infection in general practice. Mycoses 47:131-135
10. Obermair A, Binder M, Barrada M, Bancher-Todesca D, Asseryanis E, Kubista E (1998) Onycholysis in patients treated with docetaxel. Ann Oncol 9(2):230-231
11. Patten SF, Jacob C (1998) Nail bed dyschromia secondary to docetaxel therapy. Arch Dermatol 134:1167-1168
12. Robinet G, Thomas P, Perol M, Vergnenegre A, Lena H, Taytard A, Paillotin D, Bessa EH, Schuller-Lebeau MP (2000) Phase 2 study of docetaxel in inoperable advanced non-small cell lung cancer. Bull Cancer 87(3):253-258
13. Saarinen A, Jekunen A, Halme M, Pyrhonen S, Tamminen K, Boyer Roubille N, Mattson K (1996) A phase 2 trial of docetaxel in advanced non-small cell lung cancer. Anticancer Drugs 7(8):890-892
14. Scotté F, Taurani JM, Banu E, Peyromaure M, Levy E, Marsan S, Magherini E, Fabre-Guillevin E, Andrieu JM, Oudard S (2005) Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol 23(19):4424-4429
15. Stanton AW, Modi S, Mellor RH, Peters AM, Svensson WE, Levick JR, Mortimer PS (2006) A quantitative lymphoscintigraphic evaluation of lymphatic function in the swollen hands of women with lymphoedema following breast cancer treatment. Clin Sci (Lond) 110(5):553-561
16. ten Bokkel Huinink WW, Prove AM, Piccart M, Steward W, Tursz T, Wanders J, Franklin H, Clavel M, Verweij J, Alakl M (1994) A phase 2 trial with docetaxel (taxotere) in second line treatment with chemotherapy for advanced breast cancer. Ann Oncol 5(6):527-532
17. Vanhooteghem O, Richert B, Vindevoghel A, Vandenbossche L, Vandeveire A, De La Brassinne M (2000) Subungual abcess. A new ungual side-effect related to docetaxel therapy. Br J Dermatol 143:462-464
18. Wasner G, Hilpert F, Schattschneider J, Binder A, Pfisterer J, Baron R (2002) Docetaxel-induced nail changes-a neurogenic mechanism. J Neurooncol 58:167-174
19. Wiseman LR, Figgitt DP (2000) Docetaxel: an update of its use in advanced breast cancer. Drugs 59(3):621-651